FDA committee recommends COVID-19 vaccines for youngest children

An FDA advisory committee on Wednesday unanimously recommended that Moderna and Pfizer-BioNTech’s COVID-19 vaccines be authorized for children as young as 6 months old.
Members of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that Moderna’s emergency use authorization (EUA) be amended to make the company’s vaccine available for children aged 6 months through 5 years in a two-dose series, at 25 μg per dose.
The committee also recommended the FDA amend Pfizer-BioNTech’s EUA to allow infants and children aged 6 months through 4

An FDA advisory committee on Wednesday unanimously recommended that Moderna and Pfizer-BioNTech’s COVID-19 vaccines be authorized for children as young as 6 months old.
Members of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that Moderna’s emergency use authorization (EUA) be amended to make the company’s vaccine available for children aged 6 months through 5 years in a two-dose series, at 25 μg per dose.
The committee also recommended the FDA amend Pfizer-BioNTech’s EUA to allow infants and children aged 6 months through 4